Aptorum Group Ltd (APM)
NASDAQ:APM
Top Page
Aptorum Group
(NASDAQ:APM)
Select Model
Select Model
Rating:46Neutral
Price Target:
$0.78
▼(-27.20% Downside)
Action:ReiteratedDate:03/29/26
The score is primarily held down by weak financial performance—near-zero recent revenue, persistent losses, and sustained cash burn—despite a comparatively supportive balance sheet. Technicals are neutral-to-mixed with only modest near-term strength. Valuation is constrained by negative earnings and no provided dividend yield.
Positive Factors
Supportive balance sheet / improving leverage
The balance sheet shows moderate-to-improving leverage and sizable equity, giving the company financial flexibility to fund clinical programs or absorb setbacks without immediate insolvency risk. This durable cushion supports longer runway and strategic optionality over coming quarters.
Negative Factors
Near-zero recent revenue
Effectively zero revenue over recent years indicates absence of commercial products and limited organic cash generation. For a biotech, prolonged lack of revenue increases dependence on external funding and heightens execution risk for clinical-stage programs and development milestones.
Read all positive and negative factors
Positive Factors
Negative Factors
Supportive balance sheet / improving leverage
The balance sheet shows moderate-to-improving leverage and sizable equity, giving the company financial flexibility to fund clinical programs or absorb setbacks without immediate insolvency risk. This durable cushion supports longer runway and strategic optionality over coming quarters.
Read all positive factors
Aptorum Group (APM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.97M
Dividend YieldN/A
Average Volume (3M)113.32K
Price to Earnings (P/E)―
Beta (1Y)1.64
Revenue GrowthN/A
EPS Growth-1979.68%
CountryUS
Employees1
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.06
Shares Outstanding6,346,823
10 Day Avg. Volume164,850
30 Day Avg. Volume113,319
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)0.34
Price to Sales (P/S)0.00
P/FCF Ratio-4.24
Enterprise Value/Market Cap0.79
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-21.57
Enterprise Value/Ebitda-1.47
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)3.1
Revenue Forecast (FY)$106.80M
Aptorum Group Business Overview & Revenue Model
Company Description
Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeu...
How the Company Makes Money
null...
Aptorum Group Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 431.38K | 1.30M | 1.54M |
| Gross Profit | -255.00K | 0.00 | -255.00K | 10.57K | 80.06K | 81.85K |
| EBITDA | -3.75M | -1.82M | -3.76M | -9.48M | -10.32M | -25.83M |
| Net Income | -4.27M | -1.36M | -4.27M | -2.83M | -9.80M | -25.05M |
Balance Sheet | ||||||
| Total Assets | 16.13M | 18.69M | 16.13M | 20.64M | 20.87M | 21.91M |
| Cash, Cash Equivalents and Short-Term Investments | 874.24K | 3.45M | 874.24K | 2.01M | 1.99M | 8.50M |
| Total Debt | 3.35M | 3.52M | 3.35M | 3.49M | 6.85M | 217.17K |
| Total Liabilities | 4.35M | 4.90M | 4.35M | 5.26M | 13.03M | 4.40M |
| Stockholders Equity | 21.13M | 23.12M | 21.13M | 24.85M | 15.71M | 23.61M |
Cash Flow | ||||||
| Free Cash Flow | -1.19M | -1.84M | -1.19M | -7.73M | -12.51M | -14.79M |
| Operating Cash Flow | -1.19M | -1.84M | -1.19M | -7.72M | -12.32M | -14.65M |
| Investing Cash Flow | 58.62K | 0.00 | 58.62K | 624.77K | 2.44M | 16.51M |
| Financing Cash Flow | 1.43K | 4.41M | 1.43K | 4.09M | 6.63M | 2.78M |
Aptorum Group Technical Analysis
Negative
1.07
Price Trends
0.86
Positive
1.03
Negative
1.32
Negative
Market Momentum
<0.01
Positive
46.91
Neutral
25.51
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For APM, the sentiment is Negative. The current price of 1.07 is above the 20-day moving average (MA) of 0.92, above the 50-day MA of 0.86, and below the 200-day MA of 1.32, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 46.91 is Neutral, neither overbought nor oversold. The STOCH value of 25.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for APM.
Aptorum Group Risk Analysis
Aptorum Group disclosed 73 risk factors in its most recent earnings report. Aptorum Group reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Aptorum Group Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $12.28M | -0.56 | -406.72% | ― | ― | 57.97% | |
46 Neutral | $6.97M | -5.72 | -9.02% | ― | ― | -1979.68% | |
46 Neutral | $64.80M | -3.99 | -56.64% | ― | ― | -295.27% | |
42 Neutral | $22.77M | -0.09 | 0.02% | ― | ― | ― |
* Healthcare Sector Average
APM
Aptorum Group
0.86
0.11
15.54%
IMNN
Imunon
3.13
-8.22
-72.42%
DWTX
Dogwood Therapeutics
1.94
-1.36
-41.21%
AEON
AEON Biopharma
0.90
0.47
109.30%
OSRH
OSR Holdings
0.49
-1.04
-67.84%
Aptorum Group Corporate Events
Aptorum Advances DiamiR Merger with Updated S-4 Filing and March 31 Form 6-K
Apr 1, 2026
On March 31, 2026, Aptorum Group Limited reported via a Form 6-K that it is proceeding with its previously announced merger plan with U.S.-based DiamiR Biosciences Corp., under a July 14, 2025 Merger Agreement that will see a newly formed Delaware...
Aptorum Group Receives Nasdaq Notice Over Minimum Bid Price Deficiency
Mar 6, 2026
On March 6, 2026, Aptorum Group disclosed that it received a Nasdaq notice dated March 5, 2026, indicating non-compliance with the exchange’s minimum bid price requirement of $1 per share under Listing Rule 5550(a)(2). The notification does ...
Aptorum Group Sets March 10, 2026 Date for 2025 Annual General Meeting
Feb 6, 2026
Aptorum Group Limited has called its 2025 annual general meeting of shareholders for March 10, 2026, at 9:00 p.m. Hong Kong time in Hong Kong, with January 27, 2026 set as the record date for holders of its Class A and Class B ordinary shares. Sha...
Aptorum Updates Investors With Interim and Pro Forma Financials Ahead of DiamiR Merger
Jan 22, 2026
On January 21, 2026, Aptorum Group Limited filed a Form 6-K providing investors with unaudited interim condensed consolidated financial statements for the nine months ended September 30, 2025, alongside DiamiR Biosciences Corp.’s unaudited f...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.